Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 90 days matching "new medicines"

ResearchPUBMEDMay 1

Leveraging real-world data to conduct externally controlled trial for rare diseases with count-type endpoints: utilizing multiple entries - a simulation study.

Scientists are testing a new way to run drug trials for rare diseases where there aren't enough patients. Instead of only comparing patients at one specific time point, this method allows researchers to use patient information from multiple different dates. This could make it easier and faster to test new medicines for rare diseases without needing as many people in the study.

WHY IT MATTERSIf this method gets adopted by regulators, it could speed up approval timelines for rare disease treatments by allowing researchers to use more real-world patient data, potentially bringing new therapies to patients years sooner.
ℹ Good to know
ResearchPUBMEDApr 30

From data to drug: the translational impact of RaDaR, the UK national registry of rare kidney diseases.

The UK created a large database called RaDaR to collect detailed health information from patients with rare kidney diseases. With over 37,000 patients enrolled, this database helps researchers understand these diseases better, find new treatments, and run clinical trials more effectively. By gathering this information in one place, scientists can develop new medicines faster for conditions that affect relatively few people.

WHY IT MATTERSIf you have a rare kidney disease, RaDaR's data is helping researchers design better clinical trials and identify which patients might benefit from new treatments — meaning faster access to potential therapies tailored to your specific condition.
ℹ Good to know
ResearchPUBMEDMar 28

From Genomic Diagnosis to Personalized RNA Medicine: Advances in Next-Generation Sequencing and N-of-1 Antisense Oligonucleotide Therapies for Rare Genetic Diseases.

Scientists are getting better at finding rare genetic diseases using a tool called next-generation sequencing, which can read a person's DNA quickly and accurately. They're also developing new medicines called antisense oligonucleotides that can be customized for each patient to fix problems caused by genetic mutations. Together, these advances mean doctors can diagnose rare diseases faster and create personalized treatments tailored to each person's specific genetic makeup.

WHY IT MATTERSThis research shows a clear path for patients with rare genetic diseases to move from diagnosis to personalized treatment within a single medical framework, potentially reducing the diagnostic odyssey that currently takes years for many rare disease patients.
ℹ Good to knowrare monogenic disordersrare genetic diseases

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases